Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Edwards Lifesciences Corp Lowers Q3 2012 Revenue Guidance


Monday, 8 Oct 2012 04:01pm EDT 

Edwards Lifesciences Corp announced that for the third quarter of 2012, it expects total sales of $448 million. This represents a growth rate of approximately 9%, or 14% excluding the impact of foreign exchange. This compares to the Company's guidance of $465 million to $485 million provided during its second quarter earnings conference call on July 24, 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $477 million for the third quarter of 2012. 

Company Quote

103.32
0.86 +0.84%
18 Sep 2014